Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PLX Protalix BioTherapeutics

Market Closed 07-05 16:00:00 EDT

1.05

+0.01

+0.96%

盘后1.09

+0.04+3.81%

18:51 EDT

High1.10	Low1.04	Vol446.92K
Open1.07	D1 Closing1.04	Amplitude5.76%
Mkt Cap76.98M	Tradable Cap57.25M	Total Shares73.32M
T/O471.81K	T/O Rate0.82%	Tradable Shares54.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PLX","market":"US","secType":"STK","nameCN":"Protalix BioTherapeutics","latestPrice":1.05,"timestamp":1720209600000,"preClose":1.04,"halted":0,"volume":446924,"hourTrading":{"tag":"盘后","latestPrice":1.09,"preClose":1.05,"latestTime":"18:51 EDT","volume":7084,"amount":7454.63,"timestamp":1720219918752},"delay":0,"floatShares":54520149,"shares":73316084,"eps":0.065294,"marketStatus":"Market Closed","change":0.01,"latestTime":"07-05 16:00:00 EDT","open":1.07,"high":1.0999,"low":1.04,"amount":471813.19756,"amplitude":0.057596,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.065294,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1720425600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":829022400000,"exchange":"AMEX","adjPreClose":1.04,"preHourTrading":{"tag":"盘前","latestPrice":1.0514,"preClose":1.04,"latestTime":"09:28 EDT","volume":1769,"amount":1892.4528492,"timestamp":1720186133864},"postHourTrading":{"tag":"盘后","latestPrice":1.09,"preClose":1.05,"latestTime":"18:51 EDT","volume":7084,"amount":7454.63,"timestamp":1720219918752},"volumeRatio":0.2050712135710497,"impliedVol":4.3865,"impliedVolPercentile":0.9921},"requestUrl":"/m/hq/s/PLX/wiki","defaultTab":"wiki","newsList":[{"id":"2449242237","title":"PLUXEE N.V. (PLX) Receives a Buy from Kepler Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2449242237","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2449242237?lang=en_us&edition=fundamental","pubTime":"2024-07-06 09:35","pubTimestamp":1720229756,"startTime":"0","endTime":"0","summary":"In a report released on July 4, Julien Richer from Kepler Capital maintained a Buy rating on PLUXEE N.V. (PLX – Research Report), with a price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pluxee-n-v-plx-receives-a-buy-from-kepler-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pluxee-n-v-plx-receives-a-buy-from-kepler-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2448459490","title":"PLUXEE N.V. (PLX) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2448459490","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448459490?lang=en_us&edition=fundamental","pubTime":"2024-07-04 14:45","pubTimestamp":1720075546,"startTime":"0","endTime":"0","summary":"Barclays analyst Pravin Gondhale maintained a Hold rating on PLUXEE N.V. (PLX – Research Report) today and set a price target of €28.00. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pluxee-n-v-plx-gets-a-hold-from-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pluxee-n-v-plx-gets-a-hold-from-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2448875714","title":"Pluxee Ups Its FY Organic Revenue Growth Target To Around +18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448875714","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448875714?lang=en_us&edition=fundamental","pubTime":"2024-07-03 23:53","pubTimestamp":1720021998,"startTime":"0","endTime":"0","summary":"Pluxee NV :Delivers Strong Growth In Q3 And Upgrades Fiscal 2024 Organic Revenue Growth Objective.Fiscal 2024 Organic Revenue Growth Objective Upgraded To Circa +18%.Fiscal 2024 Recurring Ebitda Margin And Mid-Term Financial Objectives Reiterated.Q3 Organic Revenue Growth +17.9%.Total Revenues Reached Eur 297 Mln In Q3 2024, Growing +17.9% Organically Compared To Fiscal Q3 2023.Total Business Volumes Issued Reached Eur 18.3 Bln Over The First Nine Months Of Fiscal 2024.Mid-Term Financial Objectives Are Reaffirmed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX"],"gpt_icon":0},{"id":"2443509526","title":"Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout","url":"https://stock-news.laohu8.com/highlight/detail?id=2443509526","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443509526?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:50","pubTimestamp":1718275800,"startTime":"0","endTime":"0","summary":"Event will take place on Wednesday, June26, 2024 in New York. CARMIEL, Israel, June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell based protein expression system, today announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June26, 2024 at 8:30 a.m. Eastern Daylight Time .The investor day will feature presentations by the following key opinion leaders:. Ale Linhart, DSc, FESC , who will discuss the treatment landscape for Fabry disease and perspectives on Elfabrio , a plant cell-expressed PEGylated recombinant α-Galactosidase-A enzyme approved for adult patients with Fabry disease.Naomi Schlesinger, MD , who will discuss the current treatment landscape for uncontrolled gout and top-line results from the First-in-Human Phase I single ascending d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/protalix-biotherapeutics-host-person-investor-105000346.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protalix-biotherapeutics-host-person-investor-105000346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","ACR","BK4588","BK4139","BK4218","HST","BK4585","PLX","BK4181"],"gpt_icon":0},{"id":"2442561818","title":"Pluxee Signs Agreement To Acquire Cobee","url":"https://stock-news.laohu8.com/highlight/detail?id=2442561818","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442561818?lang=en_us&edition=fundamental","pubTime":"2024-06-12 23:54","pubTimestamp":1718207667,"startTime":"0","endTime":"0","summary":"Pluxee NV :Pluxee To Acquire Cobee, An Innovative Spanish Digital Player In Employee Benefits.Transaction To Be Fully Funded From Existing Financial Resources.Acquisition Expected To Be Neutral To Rec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"gpt_icon":0},{"id":"2441792509","title":"U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2441792509","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441792509?lang=en_us&edition=fundamental","pubTime":"2024-06-06 18:45","pubTimestamp":1717670700,"startTime":"0","endTime":"0","summary":"As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has bee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/06/2894531/11974/en/U-S-National-Institutes-of-Health-Exercises-Option-to-Fund-1-4-Million-2nd-Year-Budget-for-Pluri-s-PLX-R18-Acute-Radiation-Syndrome-Contract.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","BK4139","PLX","NHLD"],"gpt_icon":0},{"id":"2439205529","title":"Protalix BioTherapeutics to Present at the 2024 BIO International Convention","url":"https://stock-news.laohu8.com/highlight/detail?id=2439205529","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439205529?lang=en_us&edition=fundamental","pubTime":"2024-05-29 20:38","pubTimestamp":1716986280,"startTime":"0","endTime":"0","summary":"Corporate presentation scheduled forMonday, June3, 2024 at 2:30 P.M. PDT. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S.Food and Drug Administration  approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio, was approved by both the FDA and the European Medicines Agency in May 2023.Protalix has partnered with Chiesi Farmaceutici S.p.A. for the glo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-2024-bio-123800978.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protalix-biotherapeutics-present-2024-bio-123800978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIO","BK4139","BK4121","PLX","BK4585","BK4588"],"gpt_icon":0},{"id":"2435092661","title":"PLX: First Quarter Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435092661","media":"Zacks Small Cap Research","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435092661?lang=en_us&edition=fundamental","pubTime":"2024-05-15 23:27","pubTimestamp":1715786820,"startTime":"0","endTime":"0","summary":"Protalix Biotherapeutics, Inc.  announced first quarter 2024 financial and operational results in a May 10th, 2024 press release and in the filing of Form 10-Q. The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial performance. Since the beginning of the year, with respect to Elfabrio  partner Chiesi has continued its commercialization activities, obtained additional approvals and launched new studies for a pediatric indication and for approval in Japan.Revenues were $3.7 million, down 61% from $9.6 million on lower revenues from both Pfizer and Brazil. Research and development revenues were also down sharply as responsibility for further development and commercialization of Elfabrio has shifted to Chiesi;Research and development expenses fell 51% to $2.9 million from $5.8 million. Completion of the Fabry clinical program and related regulatory efforts in 2023 led to the decline. These expenditures were partially offset by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plx-first-quarter-152700120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","LU0170899867.USD","LU1057294990.SGD","SG9999001176.USD","BK4533","IE00BLSP4239.USD","BK4534","BK4588","IE00BLSP4452.SGD","LU1066053197.SGD","BK4007","IE00B19Z3B42.SGD","SG9999002224.SGD","PLX","BK4568","SG9999002232.USD","SGXZ57979304.SGD","LU1066051498.USD","PFE","BK4585","BK4550","BK4139","IE00BBT3K403.USD","BK4581","SG9999001176.SGD","LU0456855351.SGD","SG9999003800.SGD","SG9999011175.SGD","BK4592","LU0234572021.USD","LU0058720904.USD","AE","LU1023059063.AUD","LU0868494617.USD","SG9999013999.USD","BK4138","LU0289739699.SGD","IE0002270589.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2435105883","title":"Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2435105883","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435105883?lang=en_us&edition=fundamental","pubTime":"2024-05-13 15:05","pubTimestamp":1715583949,"startTime":"0","endTime":"0","summary":"Revenue from Selling Goods: $2.7 million for Q1 2024, down 27% year-over-year.Revenue from License and R&D Services: $0.1 million for Q1 2024, down 98% year-over-year.Cost of Goods Sold: $2.6 million for Q1 2024, down 16% year-over-year.Selling, General and Administrative Expenses: $3.1 million for Q1 2024, consistent with Q1 2023.Net Financial Income: $0.1 million for Q1 2024, improved from net financial expenses of $0.5 million in Q1 2023.Tax Benefit: $0.1 million for Q1 2024, compared to income taxes of $0.2 million in Q1 2023.Cash Position: $48.5 million in cash and equivalents as of March 31, 2024.GuruFocus has detected 5 Warning Signs with PLX.Protalix BioTherapeutics Inc  reported encouraging initial top-line results from the first seven cohorts of the Phase 1 study of PRX-115, leading to the extension of the study with an additional cohort.ELFABRIO, Protalix BioTherapeutics Inc 's second approved drug, continues to gain regulatory approvals globally, expanding its market presen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-plx-q1-070549405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLX"],"gpt_icon":0},{"id":"2434873626","title":"Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2434873626","media":"Insider Monkey","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434873626?lang=en_us&edition=fundamental","pubTime":"2024-05-11 22:27","pubTimestamp":1715437620,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics, Inc.  Q1 2024 Earnings Call Transcript May 10, 2024 Protalix BioTherapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (. Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2024 Financial and Business Results Conference Call. As a reminder, this conference call is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protalix. You may begin your conference.In addition to the extension of the first-in-human study, the company also decided to commence preparations for a Phase II clinical trial of PRX-115. PRX-115. To remind you is a recombinant pegylated uricase product candidate produced using our [ProCellEx]  product platform. The study is a double-blind, placebo-controlled, single ascending dose, first-in-human Phase I clinical trial that the company designed to evaluate the safety, ph","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MqP.mI8Jne4Sin.rD3GRyQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/719d50ec3e4b74a54b3d321a79733b00","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MqP.mI8Jne4Sin.rD3GRyQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/719d50ec3e4b74a54b3d321a79733b00"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protalix-biotherapeutics-inc-amex-plx-142700095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLX"],"gpt_icon":0},{"id":"2434852514","title":"Novavax, Macrogenics, Biofrontera among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2434852514","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434852514?lang=en_us&edition=fundamental","pubTime":"2024-05-10 22:00","pubTimestamp":1715349627,"startTime":"0","endTime":"0","summary":"Gainers: Novavax  +134%. ITeos Therapeutics  +39%. Caredx  +27%. Adma Biologics  +21%. Sensus Healthcare  +19%.  Losers: Macrogenics  -71%. Progyny  -23%. Biofrontera  -16%. Protalix BioTherapeutics  -14%. Revance Therapeutics  -13%.  S&P 500 Health Care Sector +0.12% to 1670.59. Health Care Equipment & Services +0.12% to 1938.81. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.18% to 1369.27.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104635-novavax-macrogenics-biofrontera-among-healthcare-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["VOO","BK4504","BK4082","MGNX","BK4585","SRTS","ESmain","BK4534","UPRO","NVAX","PLX","RVNC","SDS","BK4007","BK4588","BK4139","PGNY","OEX",".SPX","BK4154","OEF","SSO","BK4559","BK4550","CDNA","SPXU","BFRI","SPY","LU0053671581.USD","BK4581","SH","ADMA","IVV","BK4568","ITOS"],"gpt_icon":0},{"id":"2434340388","title":"Protalix BioTherapeutics GAAP EPS of -$0.06 misses by $0.04, revenue of $3.75M","url":"https://stock-news.laohu8.com/highlight/detail?id=2434340388","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434340388?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:54","pubTimestamp":1715338474,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics press release : Q1 GAAP EPS of -$0.06  misses by $0.04. Revenue of $3.75M . The Company recorded revenues from selling goods of $3.7 million for the three months ended March 31, 2024, a decrease of $1.4 million, or 27%, compared to revenues of $5.1 million for the three months ended March 31, 2023. The decrease resulted primarily from a decrease of $1.1 million in sales to Pfizer, and of $0.3 million in sales to Brazil. The decreases resulted primarily from the timing of delivery.  The Company recorded revenues from license and R&D services of $0.1 million for the three months ended March 31, 2024, a decrease of $4.4 million, or 98%, compared to revenues of $4.5 million for the three months ended March 31, 2023.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104446-protalix-biotherapeutics-gaap-eps-of-0_06-misses-0_04-revenue-of-3_75m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["PLX"],"gpt_icon":0},{"id":"2434834899","title":"Protalix BioTherapeutics' Cash, Cash Equivalents And Short-term Bank Deposits Were Approximately $48.5M At March 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434834899","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434834899?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:54","pubTimestamp":1715338462,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics' Cash, Cash Equivalents And Short-term Bank Deposits Were Approximately $48.5M At March 31, 2024","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/05/38756075/protalix-biotherapeutics-cash-cash-equivalents-and-short-term-bank-deposits-were-approximately-48","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2434348948","title":"Protalix BioTherapeutics Q1 2024 GAAP EPS $(0.06) Misses $(0.02) Estimate, Sales $3.748M Down From $9.588M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2434348948","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434348948?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:53","pubTimestamp":1715338386,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics Q1 2024 GAAP EPS $(0.06) Misses $(0.02) Estimate, Sales $3.748M Down From $9.588M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38756039/protalix-biotherapeutics-q1-2024-gaap-eps-0-06-misses-0-02-estimate-sales-3-748m-down-from-9-588m-y","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX"],"gpt_icon":0},{"id":"2434310878","title":"Press Release: Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434310878","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434310878?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:50","pubTimestamp":1715338200,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:30 a.m. EDT. CARMIEL, Israel, May 10, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.\"We are pleased to announce that initial top-line results from the first seven cohorts of the first-in-human phase I clinical trial of our recombinant uricase candidate, PRX-115, are encouraging, enabling us to expand into an eighth cohort and to begin planning a phase II trial,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"We will analyze and announce the full results from the expanded trial following the completion of the new cohort. We believe that our strong cash position is sufficient to enable th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU0289739699.SGD","LU0058720904.USD","03160","SG9999013999.USD","SG9999011175.SGD","BK4568","IE00B19Z3581.USD","SG9999002232.USD","SG9999001176.USD","BK4534","BK4099","BK4555","R","LU0170899867.USD","BK4588","IE00BBT3K403.USD","LU1057294990.SGD","BK4585","LU0868494617.USD","PFE","SG9999002224.SGD","BK4550","SG9999001176.SGD","LU1066051498.USD","BK4007","BK4232","PK","LU0456855351.SGD","SGXZ57979304.SGD","BK4139","IE00BLSP4239.USD","LU1066053197.SGD","SG9999003800.SGD","PLX","LU0122379950.USD","LU0234572021.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","BK4592","TM","BK4022","BK4533","BK4218","BK4581","BK4181","IE0002270589.USD"],"gpt_icon":0},{"id":"2434010904","title":"Protalix BioTherapeutics Q1 Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434010904","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434010904?lang=en_us&edition=fundamental","pubTime":"2024-05-10 00:27","pubTimestamp":1715272068,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics  is scheduled to announce Q1 earnings results on Friday, May 10th, before market open.The consensus EPS Estimate is -$0.02  and the consensus Revenue Estimate is $9.2M .Over the last 1 year, PLX has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4103879-protalix-biotherapeutics-q1-earnings-preview","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["PLX"],"gpt_icon":0},{"id":"2432277239","title":"Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432277239","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432277239?lang=en_us&edition=fundamental","pubTime":"2024-05-03 18:50","pubTimestamp":1714733400,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast at 8:30 a.m. EDT. CARMIEL, Israel, May 3, 2024 /PRNewswire/ --Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March31, 2024 and provide a business and clinical update on May10, 2024.Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/protalix-biotherapeutics-announce-first-quarter-105000615.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protalix-biotherapeutics-announce-first-quarter-105000615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2426243530","title":"Crypto Exchange Listing and Delisting Announcements: April 8, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2426243530","media":"Cryptonews","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2426243530?lang=en_us&edition=fundamental","pubTime":"2024-04-10 14:07","pubTimestamp":1712729224,"startTime":"0","endTime":"0","summary":"Here is our weekly collection of digital asset listing and delisting, trading pair-related announcements by crypto exchanges that we found last week and today.Have we missed something?Do you have information about new listings and/or delistings?","market":"us","thumbnail":"data:image/svg+xml;base64,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","type":0,"news_type":0,"thumbnails":["data:image/svg+xml;base64,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"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cryptonews.com/news/crypto-exchange-listing-and-delisting-announcements-april-8-2024.htm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_highlight","symbols":["FROG","PLX","SODI","BK4588","ZEUS","BK4214","LU2125910179.SGD","LU2125910336.SGD","ROSE","LU1923621640.USD","SKY","TCN","EWT","SOC","BK4139","BK4212","HODL","TD","BK4213","AITA","BK4023","SMOG","CARR","IE00B19Z6F94.USD","DCI","MKC","WISH","MCN","BK4200","BTC.USD.CC","EVR","STN","SSNC","APU","W","WIFT","BTC.USD.HKCC","BTCW","AXO","SRT","PUPS","BK4504","ATR","BARK","BK4594","BK4524","ASTO"],"gpt_icon":0},{"id":"2426503133","title":"Unlike Binance (BNB) The Pullix (PLX) Platform Allows You To Trade Forex, Metals, Indices As Well As Crypto, All With ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2426503133","media":"CoinGape","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2426503133?lang=en_us&edition=fundamental","pubTime":"2024-04-09 13:32","pubTimestamp":1712640751,"startTime":"0","endTime":"0","summary":"Unlike Binance (BNB) The Pullix (PLX) Platform Allows You To Trade Forex, Metals, Indices As Well As Crypto, All With ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMilQFodHRwczovL2NvaW5nYXBlLmNvbS9zcG9uc29yZWQvdW5saWtlLWJpbmFuY2UtYm5iLXRoZS1wdWxsaXgtcGx4LXBsYXRmb3JtLWFsbG93cy15b3UtdG8tdHJhZGUtZm9yZXgtbWV0YWxzLWluZGljZXMtYXMtd2VsbC1hcy1jcnlwdG8tYWxsLXdpdGgtbm8ta3ljL9IBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMilQFodHRwczovL2NvaW5nYXBlLmNvbS9zcG9uc29yZWQvdW5saWtlLWJpbmFuY2UtYm5iLXRoZS1wdWxsaXgtcGx4LXBsYXRmb3JtLWFsbG93cy15b3UtdG8tdHJhZGUtZm9yZXgtbWV0YWxzLWluZGljZXMtYXMtd2VsbC1hcy1jcnlwdG8tYWxsLXdpdGgtbm8ta3ljL9IBAA?oc=5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["BK4139","PLX"],"gpt_icon":0},{"id":"2425953219","title":"Can Bitcoin (BTC) Reach $80,000 Pre Halving? Trade BTC Among Other Major Cryptos on Pullix’s (PLX) New Hybrid Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2425953219","media":"CoinMarketCap","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2425953219?lang=en_us&edition=fundamental","pubTime":"2024-04-08 19:49","pubTimestamp":1712576962,"startTime":"0","endTime":"0","summary":"You can also read this news on COINTURK NEWS: Can Bitcoin (BTC) Reach $80,000 Pre Halving? Trade BTC Among Other Major Cryptos on Pullix’s (PLX) New Hybrid Platform The rise in Bitcoin’s valu","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/bbf00fcace3c420d8bd7840ac6f6b657.png","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/bbf00fcace3c420d8bd7840ac6f6b657.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6613d9cdc60a6c41c9bc880b/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["PLX","BK4139","BTC.USD.HKCC","BTC","BTC.USD.CC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protalix.com","stockEarnings":[{"period":"1week","weight":-0.1026},{"period":"1month","weight":-0.1102},{"period":"3month","weight":-0.1026},{"period":"6month","weight":-0.3966},{"period":"1year","weight":-0.4134},{"period":"ytd","weight":-0.4101}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0698},{"period":"6month","weight":0.1853},{"period":"1year","weight":0.2615},{"period":"ytd","weight":0.1669}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.705882,"avgChangeRate":0.101027},{"month":2,"riseRate":0.411765,"avgChangeRate":0.04937},{"month":3,"riseRate":0.294118,"avgChangeRate":-0.041326},{"month":4,"riseRate":0.555556,"avgChangeRate":0.048495},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.026617},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.034136},{"month":7,"riseRate":0.388889,"avgChangeRate":-0.049039},{"month":8,"riseRate":0.352941,"avgChangeRate":-0.009879},{"month":9,"riseRate":0.352941,"avgChangeRate":0.026985},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.071025},{"month":11,"riseRate":0.352941,"avgChangeRate":-0.022185},{"month":12,"riseRate":0.352941,"avgChangeRate":-0.0158}],"exchange":"AMEX","name":"Protalix BioTherapeutics","nameEN":"Protalix BioTherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protalix BioTherapeutics(PLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protalix BioTherapeutics,PLX,Protalix BioTherapeutics股票,Protalix BioTherapeutics股票老虎,Protalix BioTherapeutics股票老虎国际,Protalix BioTherapeutics行情,Protalix BioTherapeutics股票行情,Protalix BioTherapeutics股价,Protalix BioTherapeutics股市,Protalix BioTherapeutics股票价格,Protalix BioTherapeutics股票交易,Protalix BioTherapeutics股票购买,Protalix BioTherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protalix BioTherapeutics(PLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction